about
Direct oral anticoagulants: efficacy and safety in patient subgroupsThe potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.Severe mitral valve regurgitation in polymyositis.Carbimazole-induced, ANCA-associated, crescentic glomerulonephritis: case report and literature review.Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.Bivalirudin in stable angina and acute coronary syndromes.Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies.Cardiovascular complications in chronic dialysis patients.Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography.Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes.Endogenous endophthalmitis in a patient with diabetes and foot osteomyelitis.Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.C-peptide and chronic complications in patients with type-2 diabetes and the metabolic syndrome.Early versus late initiation of renal replacement therapy in patients with acute kidney injury: a meta-analysis of randomised clinical trials.Platelet reactivity in stable cardiovascular patients with chronic kidney disease.The Impact of Intradialytic Pedaling Exercise on Arterial Stiffness: A Pilot Randomized Controlled Trial in a Hemodialysis Population.Serial versus single troponin measurements for the prediction of cardiovascular events and mortality in stable chronic haemodialysis patients.Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers.Bivalirudin in ST-segment-elevation myocardial infarction: for better or worse?Echocardiographic parameters and renal outcomes in patients with preserved renal function, and mild- moderate CKD.[C-peptide: a by-product of insulin biosynthesis or an active peptide hormone?]Transient glycosuria during a urinary tract infectionDirect Factor Xa Inhibitors for Long-term Stroke Prevention in Atrial Fibrillation: Could the Lower Dose Fit All?High Ultrafiltration Rates Increase Troponin Levels in Stable Hemodialysis PatientsDuration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-AnalysisApixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation
P50
Q27023677-E9D6CFF0-2F1F-40E0-9F62-125AE3E0DDE3Q37824072-345452FA-D913-415E-9A2E-5EAC6EF6FEA8Q38050669-13DF49AC-7E20-4345-AE7D-CC37847385D4Q38076205-5C0CBC5A-6944-4BCF-99A6-1D7DB80117E4Q38169395-A0DFADFE-CA13-4A93-83CC-1FF1C9385A6EQ38413119-00D10CB8-366F-4152-9177-FF398F9D69F7Q38617639-6701D0D0-2747-473D-A88B-30CD14BFC870Q38956399-6F3DA1B8-5D48-48AB-A647-087A985B6071Q40085514-68D9DAD1-5C08-4985-A41E-0F09AA8B6B1AQ40122878-8EC532C1-1447-4A40-BA85-EE85156BF3A6Q41637661-A3605D36-636B-494A-89A4-5B891283F3F8Q42944817-8279E1B1-C59B-4D52-A780-F678A65CAEEEQ46023481-F7974F51-32EB-4C32-9166-B452BED88BBAQ47778416-49D9B6DB-D1B7-4402-AA32-E4BFA9E655FBQ48329778-83735235-EC6E-4DB5-AEB7-96FA0571397FQ50068422-065B9BED-7164-4A29-979B-FCDAA10CB106Q50752177-D455CF15-7EF8-464A-A4E1-6F414B76B94EQ50794115-B514CFAB-7F5C-4981-B986-7463034E4C25Q52618372-5655FB66-822B-4EB0-ADA1-AD6DD0535BC7Q53633859-F537EC42-E774-4234-9724-50DACADCFC2EQ55628123-B714226A-F434-4411-9E6E-5E52E971096AQ79704623-00C78E6A-8634-449C-8EDA-6E6828C978C4Q84760177-0961E32A-3D22-4D28-BA21-17144AE56667Q88581781-4AAB2FB5-E961-45C0-8018-69AB00E2E1E7Q89158300-BE21496E-DE40-44CF-82CE-F76710AB43FCQ90213322-E32D4CD8-EED4-47CA-A3EA-0D34D6DF81A5Q95659266-7DD3E90A-0F7D-4B7D-BC11-A0F893D9695D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Thomas Mavrakanas
@en
Thomas Mavrakanas
@nl
type
label
Thomas Mavrakanas
@en
Thomas Mavrakanas
@nl
prefLabel
Thomas Mavrakanas
@en
Thomas Mavrakanas
@nl
P108
P108
P31
P496
0000-0002-3368-247X